Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | GU cancer updates from ASCO 2022

Scott Tagawa • 3 Jun 2022
ASCO 2022
Genitourinary Cancer Kidney Cancer Everolimus
EVEREST

Scott T. Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, talks on genitourinary (GU) cancer updates presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the Phase III EVEREST trial (NCT01120249) investigating adjuvant everolimus, an mTOR inhibitor, for the treatment of patients with kidney cancer who have undergone surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Scott Tagawa

1:41
PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC
Scott Tagawa • 3 Jun 2023
2:57
Efficacy of sacituzumab govitecan in mUC by Trop-2 expression
Scott Tagawa • 3 Jun 2023
1:51
Future directions in the field of targeted therapies for urothelial carcinoma
Scott Tagawa • 3 Jun 2023
3:07
PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC
Scott Tagawa • 3 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals